RETMARKER S.A. (METEDA company)

RETMARKER S.A. (METEDA company) is a healthcare startup that aims to address the global issue of diabetic retinopathy, the leading cause of blindness in the working population. The company's slogan "Helping Diabetics around the world to preserve their vision" underpins its commitment to providing affordable healthcare for retinal diseases.

The proprietary Retmarker Technology and Operating Model form the foundation of the company's objective to build a valuable global business. The Retmarker device, which is a patented and certified medical device, serves as a biomarker for Diabetic Retinopathy progression. Diabetic Retinopathy affects a substantial and growing population, with 382 million cases today and an estimated 592 million by 2035.

The importance of early detection is underscored by the fact that all Diabetics should be screened at least once a year to enable timely treatment and prevent blindness. Since 2011, Retmarker has been successfully used in Diabetic Retinopathy Screening Programs, demonstrating its potential to enhance healthcare delivery without replacing medical professionals. Instead, it aims to empower them to provide superior care to those at risk of Diabetic Retinopathy.

Founded in 2008, RETMARKER S.A. operates at the intersection of AI, Health Care, and Machine Learning. The company's commitment to leveraging technology and innovation to combat a pressing global health issue positions it as an intriguing prospect for potential investors seeking meaningful impact and financial returns.